You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》騰訊為主要股東的晶泰科技循18C章申請主板上市 谷歌中生製藥等參投
香港料迎來第二隻特專科技新股,基於量子物理、人工智能及機械人自動化賦能的藥物和材料科學研發企業晶泰科技,近日循第18C章申請來港上市,獨家保薦人為中信証券。 初步招股文件顯示,該公司主要業務為藥物發現解決方案及智能化解決方案,分別提供橫跨藥物發現及研究全過程中不同模塊的解決方案,以及固態研發服務和自動化化學合成服務。 晶泰科技今年首六個月收入達到7,996.7萬元人民幣(下同),按年增長86.3%。期內經營虧損近4.35億元,對比上年同期為2.46億元;非國際財務報告準則下經調整虧損淨額錄約3.58億元,而去年同期錄2.24億元。 公司於上市前引入多家知名投資者,包括騰訊(00700.HK)、紅杉、國壽(02628.HK)、人保(01339.HK)、華興(01911.HK)、中金(03908.HK)、谷歌(GOOGL.US)、中生製藥(01177.HK)、軟銀集團等,其中騰訊為主要股東,持有公司上市前約13.66%股權。 晶泰科技表示,目前的主要商業化工作將集中在擴大現有業務、拓展至更多模態和業務場景,以及於全球擴張,集資所得將用於提升研發能力、解決方案提供能力及商業化能力。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account